China is a big area of opportunity for biotech: It has a population of about 1.4 billion, with a sizable and growing chunk of that demographic succumbing to chronic, middle-class diseases like diabetes, cancer and heart disease.
Regulation is complex, to say the least, but U.S. and European biotech companies know China is an increasingly important area not just to sell medicines, but to discover and develop them as well.
China, too, has been making a big push in the direction of innovation, and is looking to spend considerable sums on Western biopharmas to do so: In the first six months of last year, Chinese investors took part in venture capital funding rounds for U.S. biotech companies worth $1.65 billion.
Much of this cash has been used to fill in the “valley of death”: a gap between getting a promising idea into something more tangible, with cash pots of $20 million and $30 million injected into seed rounds for very young startups hoping to start the journey into the clinic.
Many saw this as the beginning of a trend, with Chinese companies and VCs increasingly looking to help bolster U.S. biotechs. But fast-forward one year, and funding is down by more than half to just $725 million, according to new figures out by Seattle-based data provider PitchBook.
This comes amid increasing trade wars between the U.S. and China, with the White House doubling down on its tough stance against alleged intellectual property theft from the country as well as higher scrutiny over how and where overseas cash injections are coming into the U.S.
In a report from the Financial Times, it appears biotechs and VC investing have been particularly hit. William Haseltine, an American biotech entrepreneur, told the London-based newspaper that he “had been forced to abandon the creation of a new company, Constructive Biology, after a Chinese investor who pledged $30 million in seed money for a fabrication laboratory pulled out.”
He said: “As soon as the Cfius programme went into place (the Committee on Foreign Investment in the U.S. which has started to more deeply review foreign investments}, and [U.S. President Donald] Trump started making a lot of noise about Cfius, [the money] began to evaporate.”
By Ben Adams
Source: Fierce Biotech
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
